A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma

This phase I/II study evaluated the safety and efficacy of a new histone deacetylase (HDAC) inhibitor, ivaltinostat, in combination with gemcitabine and erlotinib for advanced pancreatic ductal adenocarcinoma (PDAC). Patients diagnosed with unresectable, histologically confirmed PDAC who had not und...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Jung Hyun, Jung, Dawoon E., Lee, Hee Seung, Park, Soo Been, Chung, Moon Jae, Park, Jeong Youp, Bang, Seungmin, Park, Seung Woo, Cho, Sangsook, Song, Si Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545559/
https://www.ncbi.nlm.nih.gov/pubmed/35657348
http://dx.doi.org/10.1002/ijc.34144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545559/
https://www.ncbi.nlm.nih.gov/pubmed/35657348
http://dx.doi.org/10.1002/ijc.34144

Ejemplares similares